Soria Jean-Charles, Felip Enriqueta, Cobo Manuel, Lu Shun, Syrigos Konstantinos, Lee Ki Hyeong, . . . et al. (2015). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase 3 trial.
Chicago Style (17th ed.) CitationSoria Jean-Charles, et al. Afatinib Versus Erlotinib as Second-line Treatment of Patients with Advanced Squamous Cell Carcinoma of the Lung (LUX-Lung 8): An Open-label Randomised Controlled Phase 3 Trial. 2015.
MLA idézésSoria Jean-Charles, et al. Afatinib Versus Erlotinib as Second-line Treatment of Patients with Advanced Squamous Cell Carcinoma of the Lung (LUX-Lung 8): An Open-label Randomised Controlled Phase 3 Trial. 2015.
Figyelem: ezek az hivatkozások nem 100%-ban pontosak..